Werewolf Therapeutics, Inc.

NASDAQ:HOWL

Biotechnology

Healthcare
$1.03 +6.12%

+$0.06 today

Market cap
$50.06M
Beta
0.29
P/E (TTM)
-1.4
EPS (TTM)
-$0.71
52W Low $0.27High $1.83

Volume 1.85M

Average 5.09M

HOWL Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Werewolf Therapeutics, Inc.NASDAQ: HOWL

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin at 88.3%

Gross margin was 88.3% in Q2 FY2026. On a trailing-twelve-month basis it was 86.4%.

Context

  • Gross margin widened in 1 of the last 2 fiscal years.
  • FY2024 was the lowest level in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
88.3%— QoQ
Last fiscal yearDec 2025
—— YoY
LTMJun 2026
86.4%— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2024
3.8%
Year-over-year change
-87.4pp

Gross Margin vs competitors

How HOWL compares with its peers on the latest reported figures

  • HOWL's LTM Jun 2026 gross margin of 86.4% is the 3rd highest of the 5 companies compared; the peer median is 68.4%.
HOWL Competitors Peer median
Gross Margin for HOWL and competitors
Company Period LTM level YoY 3-year change
INMBINmune Bio, Inc.FY2025100.0% +0.0 pp+0.0 pp
CUECue Biopharma, Inc.LTM Mar 202699.8% -0.2 pp+0.0 pp
HOWLWerewolf Therapeutics, Inc.LTM Jun 202686.4% ——
NRXPNRx Pharmaceuticals, Inc.LTM Mar 202637.1% ——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-360.9% -377.1 pp—
SPRBSpruce Biosciences, Inc.FY2025— ——
OSTXOS Therapies IncorporatedFY2025— ——
ACETAdicet Bio, Inc.FY2025— ——
Peer median (excluding HOWL) 68.4%-0.2 pp+0.0 pp

Competitors are the stored peer set for HOWL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue016.4M19.94M1.89M0
Cost of Revenue02.51M1.76M1.81M1.63M
Gross Profit013.89M18.18M71K(1.63M)
Gross Margin—84.7%91.2%3.8%—
Research & Development35.27M53.76M41.78M56.43M44.83M
Selling, General & Admin14.82M21.5M18.67M19.05M15.85M
Operating Expenses50.09M69.95M58.68M73.67M59.04M
Depreciation & Amortization216K1.1M1.76M1.81M1.63M
EBITDA(49.77M)(52.71M)(32.47M)(64.05M)(53.91M)
EBITDA Margin—-321.4%-162.8%-3397.6%—
Operating Income(50.09M)(56.06M)(40.5M)(73.59M)(60.68M)
Operating Margin—-341.8%-203.1%-3904.2%—
Interest Income104K1.91M7.42M6.67M3.11M
Interest Expense003.14M4.66M5.27M
Other Income / Expenses104K2.25M3.14M3.08M(145K)
Income Before Tax(49.98M)(53.81M)(37.37M)(70.52M)(60.82M)
Pre-Tax Margin—-328.1%-187.4%-3740.8%—
Income Tax Expense00000
Net Income(49.98M)(53.81M)(37.37M)(70.52M)(60.82M)
Net Margin—-328.1%-187.4%-3740.8%—
EPS (Basic)(10.94)(1.86)(1.05)(1.63)(1.32)
EPS (Diluted)(10.94)(1.86)(1.05)(1.63)(1.33)
Weighted Avg Shares18.46M28.86M35.65M43.33M46.02M
Weighted Avg Shares (Diluted)18.46M28.86M35.65M43.86M46.81M

Werewolf Therapeutics, Inc.

NASDAQ:HOWL

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.